{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T23:25:27Z","timestamp":1784417127454,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T00:00:00Z","timestamp":1719100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T00:00:00Z","timestamp":1719100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00284-024-03761-2","type":"journal-article","created":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T19:01:49Z","timestamp":1719169309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Zoliflodacin, a Spiropyrimidinetrione Antibiotic, Against Gram-Negative Pathogens"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-7225","authenticated-orcid":false,"given":"Ozlem","family":"Oyardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Nur","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Dosler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,23]]},"reference":[{"key":"3761_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9040196","author":"S Morris","year":"2020","unstructured":"Morris S, Cerceo E (2020) Trends, epidemiology, and management of multi-drug resistant gram-negative bacterial infections in the hospitalized setting. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics9040196","journal-title":"Antibiotics"},{"issue":"6","key":"3761_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2019.1610392","volume":"17","author":"GL Voulgaris","year":"2019","unstructured":"Voulgaris GL, Voulgari ML, Falagas ME (2019) Developments on antibiotics for multidrug resistant bacterial gram-negative infections. Expert Rev Anti Infect Ther 17(6):387\u2013401. https:\/\/doi.org\/10.1080\/14787210.2019.1610392","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3761_CR3","unstructured":"WHO (2017) Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis (No. WHO\/EMP\/IAU\/2017.12)"},{"issue":"1","key":"3761_CR4","doi-asserted-by":"publisher","first-page":"e56033","DOI":"10.15252\/embr.202256033","volume":"24","author":"S Walesch","year":"2023","unstructured":"Walesch S, Birkelbach J, J\u00e9z\u00e9quel G, Haeckl FPJ, Hegemann JD, Hesterkamp T, Hirsch AKH, Hammann P, M\u00fcller R (2023) Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials. EMBO Rep 24(1):e56033. https:\/\/doi.org\/10.15252\/embr.202256033","journal-title":"EMBO Rep"},{"key":"3761_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.684515","volume":"11","author":"NK Boyd","year":"2021","unstructured":"Boyd NK, Teng C, Frei CR (2021) Brief overview of approaches and challenges in new antibiotic development: a focus on drug repurposing. Front Cell Infect Microbiol 11:684515. https:\/\/doi.org\/10.3389\/fcimb.2021.684515","journal-title":"Front Cell Infect Microbiol"},{"key":"3761_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020200","author":"J Murugaiyan","year":"2022","unstructured":"Murugaiyan J, Kumar PA, Rao GS, Iskandar K, Hawser S, Hays JP, Mohsen Y, Adukkadukkam S, Awuah WA, Jose RAM, Sylvia N, Nansubuga EP, Tilocca B, Roncada P, Roson-Calero N, Moreno-Morales J, Amin R, Kumar BK, Kumar A, Toufik AR, Zaw TN, Akinwotu OO, Satyaseela MP, van Dongen MBM (2022) Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics. Antibiotics. https:\/\/doi.org\/10.3390\/antibiotics11020200","journal-title":"Antibiotics"},{"key":"3761_CR7","volume-title":"2021 antibacterial agents in clinical and preclinical development: an overview and analysis","author":"WHO","year":"2022","unstructured":"WHO (2022) 2021 antibacterial agents in clinical and preclinical development: an overview and analysis. World Health Organization"},{"key":"3761_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.874176","volume":"13","author":"S Jacobsson","year":"2022","unstructured":"Jacobsson S, Golparian D, Oxelbark J, Franceschi F, Brown D, Louie A, Drusano G, Unemo M (2022) Pharmacodynamic evaluation of zoliflodacin treatment of Neisseria gonorrhoeae strains with amino acid substitutions in the zoliflodacin target GyrB using a dynamic hollow fiber infection model. Front Pharmacol 13:874176. https:\/\/doi.org\/10.3389\/fphar.2022.874176","journal-title":"Front Pharmacol"},{"issue":"5","key":"3761_CR9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jac\/dkab024","volume":"76","author":"M Unemo","year":"2021","unstructured":"Unemo M, Ahlstrand J, S\u00e1nchez-Bus\u00f3 L, Day M, Aanensen D, Golparian D, Jacobsson S, Cole MJ (2021) High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018. J Antimicrob Chemother 76(5):1221\u20131228. https:\/\/doi.org\/10.1093\/jac\/dkab024","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3761_CR10","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1128\/aac.04456-14","volume":"59","author":"RA Alm","year":"2015","unstructured":"Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, Lewis LA, Su X, Huband MD, Gardner H, Mueller JP (2015) Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 59(3):1478\u20131486. https:\/\/doi.org\/10.1128\/aac.04456-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"3761_CR11","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1093\/jac\/dkz376","volume":"74","author":"S Foerster","year":"2019","unstructured":"Foerster S, Drusano G, Golparian D, Neely M, Piddock LJV, Alirol E, Unemo M (2019) In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae. J Antimicrob Chemother 74(12):3521\u20133529. https:\/\/doi.org\/10.1093\/jac\/dkz376","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3761_CR12","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","volume":"6","author":"PA Bradford","year":"2020","unstructured":"Bradford PA, Miller AA, O\u2019Donnell J, Mueller JP (2020) Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae including multi-drug-resistant isolates. ACS Infect Dis 6(6):1332\u20131345. https:\/\/doi.org\/10.1021\/acsinfecdis.0c00021","journal-title":"ACS Infect Dis"},{"key":"3761_CR13","unstructured":"CLSI (2023) Performance Standards for Antimicrobial Susceptibility Testing. 33rd ed. CLSI supplement M100. In. Clinical and Laboratory Standards Institute, USA"},{"key":"3761_CR14","unstructured":"CLSI (2006) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Seventh Edition: M07. In. Clinical and Laboratory Standards Institute, Wayne, PA, USA"},{"issue":"1","key":"3761_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52(1):1. https:\/\/doi.org\/10.1093\/jac\/dkg301","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3761_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1128\/aac.04124-14","volume":"59","author":"MD Huband","year":"2015","unstructured":"Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF, Mueller JP (2015) In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase\/topoisomerase inhibitor with potent activity against gram-positive, fastidious gram-negative, and atypical bacteria. Antimicrob Agents Chemother 59(1):467\u2013474. https:\/\/doi.org\/10.1128\/aac.04124-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"3761_CR17","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","volume":"379","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Se\u00f1a AC, Long J, Wierzbicki MR, Kwak H, Johnson SM, Lawrence K, Mueller J (2018) Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med 379(19):1835\u20131845. https:\/\/doi.org\/10.1056\/NEJMoa1706988","journal-title":"N Engl J Med"},{"key":"3761_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01479-19","author":"S Jacobsson","year":"2019","unstructured":"Jacobsson S, Kularatne R, Kittiyaowamarn R, Maseko V, Paopang P, Sangprasert P, Sirivongrangson P, Piddock L, Wi T, Alirol E, Unemo M (2019) High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015\u20132017). Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01479-19","journal-title":"Antimicrob Agents Chemother"},{"key":"3761_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00863-20","author":"W Le","year":"2021","unstructured":"Le W, Su X, Lou X, Li X, Gong X, Wang B, Genco CA, Mueller JP, Rice PA (2021) Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing China (2014\u20132018). Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00863-20","journal-title":"Antimicrob Agents Chemother"},{"key":"3761_CR20","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.3389\/fmicb.2018.03198","volume":"9","author":"RL Ferreira","year":"2018","unstructured":"Ferreira RL, da Silva BCM, Rezende GS, Nakamura-Silva R, Pitondo-Silva A, Campanini EB, Brito MCA, da Silva EML, Freire CCM, da Cunha AF, Pranchevicius MDS (2018) High prevalence of multidrug-resistant Klebsiella pneumoniae harboring several virulence and \u03b2-Lactamase encoding genes in a Brazilian intensive care unit. Front Microbiol 9:3198. https:\/\/doi.org\/10.3389\/fmicb.2018.03198","journal-title":"Front Microbiol"},{"issue":"8","key":"3761_CR21","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00284-018-1475-3","volume":"75","author":"G Ripabelli","year":"2018","unstructured":"Ripabelli G, Tamburro M, Guerrizio G, Fanelli I, Flocco R, Scutell\u00e0 M, Sammarco ML (2018) Tracking multidrug-resistant Klebsiella pneumoniae from an Italian hospital: molecular epidemiology and surveillance by PFGE, RAPD and PCR-based resistance genes prevalence. Curr Microbiol 75(8):977\u2013987. https:\/\/doi.org\/10.1007\/s00284-018-1475-3","journal-title":"Curr Microbiol"},{"issue":"9","key":"3761_CR22","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/jac\/dkx179","volume":"72","author":"A Both","year":"2017","unstructured":"Both A, B\u00fcttner H, Huang J, Perbandt M, Belmar Campos C, Christner M, Maurer FP, Kluge S, K\u00f6nig C, Aepfelbacher M, Wichmann D, Rohde H (2017) Emergence of ceftazidime\/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother 72(9):2483\u20132488. https:\/\/doi.org\/10.1093\/jac\/dkx179","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"3761_CR23","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/jac\/dkz330","volume":"74","author":"S G\u00f6ttig","year":"2019","unstructured":"G\u00f6ttig S, Frank D, Mungo E, Nolte A, Hogardt M, Besier S, Wichelhaus TA (2019) Emergence of ceftazidime\/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. J Antimicrob Chemother 74(11):3211\u20133216. https:\/\/doi.org\/10.1093\/jac\/dkz330","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"3761_CR24","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1128\/aac.01165-15","volume":"59","author":"RM Humphries","year":"2015","unstructured":"Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A (2015) First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 59(10):6605\u20136607. https:\/\/doi.org\/10.1128\/aac.01165-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3761_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/femsre\/fux013","volume":"41","author":"S Navon-Venezia","year":"2017","unstructured":"Navon-Venezia S, Kondratyeva K, Carattoli A (2017) Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 41(3):252\u2013275. https:\/\/doi.org\/10.1093\/femsre\/fux013","journal-title":"FEMS Microbiol Rev"},{"issue":"9","key":"3761_CR26","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.3390\/molecules26092671","volume":"26","author":"M Terreni","year":"2021","unstructured":"Terreni M, Taccani M, Pregnolato M (2021) New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. Molecules 26(9):2671. https:\/\/doi.org\/10.3390\/molecules26092671","journal-title":"Molecules"},{"key":"3761_CR27","unstructured":"CLSI (2021) Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. CLSI supplement M100. . In. Clinical and Laboratory Standards Institute, Wayne, PA, USA"},{"key":"3761_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00567-19","author":"AA Miller","year":"2019","unstructured":"Miller AA, Traczewski MM, Huband MD, Bradford PA, Mueller JP (2019) Determination of MIC quality control ranges for the novel gyrase inhibitor zoliflodacin. J Clin Microbiol. https:\/\/doi.org\/10.1128\/jcm.00567-19","journal-title":"J Clin Microbiol"},{"issue":"5","key":"3761_CR29","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/infdis\/jis766","volume":"207","author":"EB Hirsch","year":"2013","unstructured":"Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, Tam VH (2013) Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis 207(5):786\u2013793. https:\/\/doi.org\/10.1093\/infdis\/jis766","journal-title":"J Infect Dis"},{"issue":"1","key":"3761_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244673","volume":"16","author":"JC Ontong","year":"2021","unstructured":"Ontong JC, Ozioma NF, Voravuthikunchai SP, Chusri S (2021) Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates. PLoS ONE 16(1):e0244673. https:\/\/doi.org\/10.1371\/journal.pone.0244673","journal-title":"PLoS ONE"},{"issue":"1","key":"3761_CR31","first-page":"19","volume":"9","author":"N Madadi-Goli","year":"2017","unstructured":"Madadi-Goli N, Moniri R, Bagheri-Josheghani S, Dasteh-Goli N (2017) Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii. Iran J Microbiol 9(1):19\u201325","journal-title":"Iran J Microbiol"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-024-03761-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-024-03761-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-024-03761-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T04:05:29Z","timestamp":1721448329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-024-03761-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,23]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3761"],"URL":"https:\/\/doi.org\/10.1007\/s00284-024-03761-2","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,23]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors have declared that no ethical issues exist. This article does not contain any studies with human participants or animals performed by any of the author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"241"}}